{"url_path":"/sec/plyx/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/2075320/0001213900-26-056973-index.html","accession_number":"0001213900-26-056973","cik":"0002075320","ticker":"PLYX","issuer_name":"Polaryx Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/2075320/0001213900-26-056973-index.html","primary_entity_key":"0002075320","primary_entity_name":"Polaryx Therapeutics, Inc."},"word_count":384,"has_tables":true,"body_markdown":"Item 6. Exhibits\n\n \n\nExhibit No.\n \nDescription\n\n3.1\n \n[Amended and Restated Articles of Incorporation of the registrant (filed with the SEC as Exhibit 3.3 to the Company’s Form S-1/A filed on January 14, 2026).](http://www.sec.gov/Archives/edgar/data/2075320/000121390026004079/ea025123907ex3-3_polaryx.htm)\n\n3.2\n \n[Amended and Restated Bylaws of the registrant (filed with the SEC as Exhibit 3.4 to the Company’s Form S-1/A filed on January 14, 2026)](http://www.sec.gov/Archives/edgar/data/2075320/000121390026004079/ea025123907ex3-4_polaryx.htm).\n\n10.1\n \n[Addendum #2 to Consultancy Agreement, dated March 23, 2026, by and between Mstone Partners Healthcare Limited and Polaryx Therapeutics, Inc. (filed with the SEC as Exhibit 10.13 to the Company’s Form 10-K filed on March 24, 2026).](https://www.sec.gov/Archives/edgar/data/2075320/000121390026033064/ea028171901ex10-13.htm)\n\n10.2#\n \n[Polaryx Therapeutics, Inc. 2025 Equity Incentive Plan (incorporated by reference to Exhibit 10.5 to the Company’s Registration Statement on Form S-1 filed on November 21, 2025).](https://www.sec.gov/Archives/edgar/data/2075320/000121390025113249/ea025123904ex10-5_polaryx.htm)\n\n31.1*\n \n[Certification of the principal executive officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934](ea028929901ex31-1.htm)\n\n31.2*\n \n[Certification of the principal financial officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934](ea028929901ex31-2.htm)\n\n32.1(1)\n \n[Certification of the principal executive officer and principal financial officer pursuant to 18 U.S.C. Section 1350 and Rule 13a-14(b) under the Securities Exchange Act of 1934](ea028929901ex32-1.htm)\n\n101.INS*\n \nInline XBRL Instance Document\n\n101.SCH*\n \nInline XBRL Taxonomy Extension Schema Document\n\n101.CAL*\n \nInline XBRL Taxonomy Extension Calculation Linkbase Document\n\n101.DEF*\n \nInline XBRL Taxonomy Extension Definition\n\n101.LAB*\n \nInline XBRL Taxonomy Extension Label Linkbase Document\n\n101.PRE*\n \nInline XBRL Taxonomy Extension Presentation Linkbase Document\n\n104*\n \nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n*\nFiled herewith.\n\n \n\n#\nIndicates management contract or compensatory plan or arrangement.\n\n \n \n\n(1)\nFurnished herewith and not to be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liability of such section, and not to be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act.\n\n \n\n29 \n\n \n\n \n\nSIGNATURES\n\n \n\nPursuant to the requirements of the Securities\nExchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\n \nPolaryx Therapeutics, Inc.\n\n \n \n \n\nDate: May 14, 2026\n \n \n\n \n \n \n\n \nBy: \n/s/ Alex Yang\n\n \n \nAlex Yang\n\n \n \n*Chief Executive Officer*\n\n \n \n*(Principal Executive Officer)*\n\n \n \n \n\nDate: May 14, 2026\n \n \n\n \n \n \n\n \nBy:\n/s/ G. Michael Landis\n\n \n \nG. Michael Landis\n\n \n \n*Chief Financial Officer*\n\n \n \n*(Principal Financial and Accounting Officer)*\n\n \n\n30"}